<DOC>
	<DOCNO>NCT02172144</DOCNO>
	<brief_summary>Study investigate effect BI 1744 CL QT/QTc interval ECG ( electrocardiogram ) comparison placebo</brief_summary>
	<brief_title>Via RespimatÂ® Inhaled BI 1744 CL Compared Moxifloxacin Placebo Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>All participant study healthy male female , range 21 50 year age , body mass index ( BMI ) within 18.5 29.9 kg/m2 ( BMI calculation : weight kilogram divide square height meter ) . In accordance Good Clinical Practice local legislation volunteer give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , clinically relevant electrolyte disturbance Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic clinically relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( within two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day male &gt; 20 g/day female ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Any laboratory value outside reference range indicative underlying disease poor health Excessive physical activity within last week trial trial Hypersensitivity treatment medication , moxifloxacin and/or relate drug class Previous tendon disease relate quinolone treatment Congenital document acquire QT prolongation , previous history symptomatic arrhythmia Pulse rate screen &gt; 80 bpm &lt; 45 bpm Any screen ECG value outside reference range clinical relevance include , limited PR ( Pulse rate ) interval &gt; 220 m , QRS interval &gt; 115 m , QTcB &gt; 450 m , QT ( uncorrected ) &gt; 470 m For Female Subjects : Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilisation , intrauterinepressure , oral contraceptive ) Inability maintain adequate contraception whole study period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>